In this regard, results from recent studies have suggested that the hyperactivation of EGFR signaling could be one of major pathway that drives the adaptation of tumor cells to cisplatin, thereby contributing to the generation of cancer cells with better survival advantages. The gene discussed is EGFR; the disease is cancer.